This grant, offered by the HIRN Consortium on Beta Cell Death and Survival (CBDS), supports research exploring human pancreatic tissues and immune responses to uncover early Type 1 Diabetes (T1D) disease processes. The funding aims to identify specific signaling pathways contributing to the asymptomatic phase of T1D, discover early biomarkers, develop diagnostic tools for detection and staging, and validate therapeutic targets for preventative or early treatment strategies. Successful applicants will join the CBDS, which focuses on understanding mechanisms of beta cell stress and destruction to protect residual beta cell mass and prevent autoimmunity. This opportunity emphasizes human disease biology, excluding animal models and clinical trials, contributing to the broader mission of the Human Islet Research Network to safeguard functional beta cell mass in T1D patients.
Opportunity ID: 353307
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DK-23-007 |
| Funding Opportunity Title: | Discovery of Early Type 1 Diabetes Disease Processes in the Human Pancreas [HIRN Consortium on Beta Cell Death and Survival (CBDS)] (U01 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Food and Nutrition Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.847 — Diabetes, Digestive, and Kidney Diseases Extramural Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Apr 01, 2024 |
| Last Updated Date: | Apr 01, 2024 |
| Original Closing Date for Applications: | Jul 09, 2024 |
| Current Closing Date for Applications: | Jul 09, 2024 |
| Archive Date: | Aug 14, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $550,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts State governments Special district governments Public housing authorities/Indian housing authorities Others (see text field entitled “Additional Information on Eligibility” for clarification) County governments City or township governments Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Notice of Funding Opportunity (NOFO) requests applications to explore human pancreatic tissues and the immune compartment for the discovery of specific signaling or processing pathways that may contribute to the asymptomatic phase of T1D, the discovery of early biomarkers of T1D pathogenesis, the development of diagnostic tools for the detection and staging of early T1D in at-risk or recently-diagnosed individuals, and/or the identification and biological validation of therapeutic targets for the development of preventative or early treatment strategies. Successful applicants will join the Consortium on Beta Cell Death and Survival (CBDS), whose mission is to better define and detect the mechanisms of beta cell stress and destruction central to the development of T1D in humans, with the long-term goal of protecting the residual beta cell mass in T1D patients as early as possible in the disease process, and of preventing the progression to autoimmunity. The CBDS is part of a collaborative research framework, the Human Islet Research Network (HIRN, https://hirnetwork.org/), whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This NOFO will only support studies with a primary focus on increasing our understanding of human disease biology (as opposed to rodent or other animal models). This NOFO will not accept applications proposing a clinical trial. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-23-007.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 353307 Full Announcement-RFA-DK-23-007 -> RFA-DK-23-007-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00285663 | Jun 10, 2024 | Jul 09, 2024 | View |
Package 1
Mandatory forms
353307 RR_SF424_5_0-5.0.pdf
353307 PHS398_CoverPageSupplement_5_0-5.0.pdf
353307 RR_OtherProjectInfo_1_4-1.4.pdf
353307 PerformanceSite_4_0-4.0.pdf
353307 RR_KeyPersonExpanded_4_0-4.0.pdf
353307 PHS398_ResearchPlan_5_0-5.0.pdf
353307 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
353307 RR_Budget_3_0-3.0.pdf
353307 RR_SubawardBudget30_3_0-3.0.pdf
353307 PHS398_ModularBudget_1_2-1.2.pdf
353307 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
